Basem M Mishriky
8PUBLICATIONS
5CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Feb 16, 2024
Comparative analysis of hospitalization risk for incident heart failure in non-Hispanic Black versus non-Hispanic White individuals with type 2 diabetes on empagliflozin (Empa-AA): Insights from real-world data.Basem M Mishriky, Doyle M Cummings, Yuanyuan Fu
|Aug 31, 2023
A meta-analysis of randomized controlled trials evaluating sodium-glucose co-transporter 2 inhibitors and incidental atrial fibrillation-Is there a true benefit?Basem M Mishriky, Doyle M Cummings, James R Powell
|Jan 13, 2021
GLP-1 RA and atrial fibrillation in the cardiovascular outcome trials.Zahra Hamedi, Basem M Mishriky, Victor Okunrintemi
|Oct 01, 2020
Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials.Victor Okunrintemi, Basem M Mishriky, James R Powell
|May 13, 2020
Should Baseline Hemoglobin A1c or Dose of SGLT-2i Guide Treatment With SGLT-2i Versus DPP-4i in People With Type 2 Diabetes? A Meta-Analysis and Systematic Review.Jarrod L Uhrig, Stephanie O Page, Basem M Mishriky
|Jul 18, 2019
Insulin therapy in patients with type 2 diabetes and high insulin resistance is associated with increased risk of complications and mortality.Carlos E Mendez, Rebekah J Walker, Christian R Eiler
Pageof 2
